Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML).
第一作者:
U,Popat
第一单位:
Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX, USA. udaypopat@hotmail.com
作者:
医学主题词
急性病(Acute Disease);成年人(Adult);老年人(Aged);抗淋巴细胞血清(Antilymphocyte Serum);女(雌)性(Female);随访研究(Follow-Up Studies);移植物抗宿主病(Graft vs Host Disease);人类(Humans);免疫抑制剂(Immunosuppressive Agents);白血病, 髓样(Leukemia, Myeloid);主要组织相容性复合物(Major Histocompatibility Complex);男(雄)性(Male);中年人(Middle Aged);干细胞移植(Stem Cell Transplantation);时间因素(Time Factors);移植嵌合体(Transplantation Chimera);移植, 同种(Transplantation, Homologous);治疗结果(Treatment Outcome)
DOI
10.1038/sj.bmt.1705229
PMID
16462757
发布时间
2019-12-10
- 浏览8
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



